Business Context and Reporting Period
The filing is EyeGate Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, although the request metadata identifies Kiora Pharmaceuticals. The filing describes a clinical-stage ophthalmology company with no approved commercial products and one operating segment focused on research and development.
Lead programs include EGP-437, a dexamethasone phosphate and EyeGate II iontophoresis combination product for anterior uveitis and post-cataract inflammation and pain, and EyeGate Ocular Bandage Gel, a CMHA-S-based product acquired through the March 2016 Jade Therapeutics acquisition.
Key Financial Metrics
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Collaboration revenue | $0.669 million | $0 | +$0.669 million |
| Research and development expense | $8.423 million | $2.717 million | +$5.705 million |
| General and administrative expense | $5.594 million | $3.960 million | +$1.633 million |
| Total operating expenses | $14.016 million | $6.678 million | +$7.338 million |
| Net loss | $13.343 million | $8.388 million | Loss increased $4.955 million |
| Net loss attributable to common stockholders | $13.343 million | $16.615 million | Loss decreased $3.272 million |
| Net loss per share | $1.51 | $2.70 | Improved |
| Net cash used in operating activities | $8.413 million | $4.459 million | Use increased $3.954 million |
| Cash and cash equivalents at year-end | $3.635 million | $8.394 million | Decreased $4.759 million |
The company had no debt other than ordinary-course trade payables and capital lease obligations. Total liabilities were $10.060 million, including $4.225 million of deferred revenue, $1.210 million of contingent consideration related to the Jade acquisition, and a $1.526 million deferred tax liability. Stockholders’ deficit was $0.329 million at December 31, 2016.
The company reported no material off-balance-sheet arrangements. Contractual obligations totaled $1.718 million, primarily $1.389 million of clinical research purchase obligations, $0.267 million of leases and $0.063 million of licensing obligations.
Material Changes Versus the Prior Comparable Period
- Revenue began in 2016, primarily from U.S. government grants and collaboration-related activities following the Jade acquisition.
- R&D spending increased substantially due to the ongoing confirmatory Phase 3 anterior uveitis trial, the post-cataract Phase 1b/2a trial, EyeGate OBG development and expansion of the product pipeline.
- General and administrative expenses increased as operations expanded, including activities associated with Jade.
- Interest expense declined from $1.934 million in 2015 to $0.275 million in 2016, while the 2015 deemed preferred-stock dividend of $8.222 million did not recur. Consequently, net loss attributable to common stockholders improved despite the higher operating loss.
- Shares outstanding increased from 7.657 million at December 31, 2015 to 10.131 million at December 31, 2016, reflecting the Jade acquisition, equity financing and conversion of Series A preferred stock.
- The company acquired Jade for approximately $2.910 million, consisting primarily of common stock, assumed obligations and contingent consideration. Jade contributed approximately $0.509 million of net loss after acquisition.
Clinical Outlook, Guidance and Unusual Items
- The company expected to initiate a double-masked EyeGate OBG trial in the second quarter of 2017 and targeted a 510(k) De Novo filing and CE Mark filing by year-end 2017.
- For post-cataract inflammation and pain, management planned a Phase 2b trial in 2017 and targeted a supplemental NDA filing in the second half of 2018.
- The confirmatory Phase 3 anterior uveitis trial was enrolling, with top-line data expected in the second half of 2017 and an NDA filing targeted for year-end 2017 if non-inferiority criteria were met.
- The completed anterior uveitis Phase 3 trial produced response rates comparable to prednisolone acetate but fell just outside the prespecified non-inferiority margin and did not achieve statistical significance in the intent-to-treat population.
- The 39-subject EyeGate OBG pilot reported positive top-line data after year-end. Complete wound closure by Day 3 was 83.3% for OBG alone versus 53.8% for the standard-of-care arm.
- On February 21, 2017, after the reporting period, the company entered a new Valeant license agreement for post-operative ocular inflammation and pain. It received a $4.0 million upfront payment and became eligible for approximately $99.0 million of development and commercial milestones plus royalties.
- Management stated that year-end cash and expected first-half 2017 receipts would fund planned operations for approximately five months. The independent auditor included a going-concern explanatory paragraph, and management stated that substantial additional financing was required.
- In-process research and development acquired from Jade was recorded at $3.912 million and will not be amortized until the related development program is completed; the filing does not indicate FDA approval has been obtained.
Principal Risks and Contingencies
- The company has a history of significant losses, negative operating cash flow and no commercial product revenue. It may never achieve profitability.
- Additional equity, debt, grant or partnership financing is required; unavailable financing could delay, reduce or terminate development programs and may dilute stockholders.
- EGP-437 depends on successful confirmatory Phase 3 results, a separate corneal endothelial-cell safety trial, regulatory approval, manufacturing validation and market acceptance.
- Clinical trials may fail, be delayed, experience enrollment problems or produce safety findings that require additional studies or prevent approval.
- The company relies on contract research organizations and third-party manufacturers and had no committed commercial supply arrangements or redundant sources for certain materials and services.
- Valeant agreements may be terminated under specified circumstances, and future milestones and royalties are contingent on development, regulatory and commercial achievements.
- Competition from established corticosteroid products, generic therapies and better-funded pharmaceutical companies could limit adoption and pricing.
- Patent validity, freedom to operate, reimbursement, regulatory compliance, product liability and integration of Jade remain material uncertainties.
Investor Verification Checklist
- Confirm the issuer identity: the supplied filing is for EyeGate Pharmaceuticals, Inc., not Kiora Pharmaceuticals.
- Verify the company’s current cash position, financing activity and runway following the $4.0 million Valeant upfront payment and the planned restart of its ATM program.
- Review confirmatory Phase 3 anterior uveitis results and determine whether the prespecified non-inferiority criteria were met.
- Assess the required endothelial-cell safety trial, NDA timing and the FDA’s eventual regulatory decisions.
- Verify EyeGate OBG’s subsequent clinical results and progress toward the targeted De Novo submission.
- Review dilution from outstanding warrants, options, potential ATM sales and other equity instruments.
- Evaluate the going-concern disclosure, contingent Jade earn-out, deferred revenue and remaining contractual obligations.